Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery? Laiba Immad Thu, August 13, 2026 at 3:49 PM PDT 5 min read ALC RXST Two ophthalmic technology leaders, Alcon Inc. (NYSE: ALC ) and RxSight, Inc. (NASDAQ: RXST ), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight's proprietary light-adjustable technology, which allows eye surgeons to fine-tune a patient's vision using UV light after surgery, with Alcon's global commercial footprint and surgical equipment portfolio, the agreement validates RxSight's technology while expanding Alcon's premium lens offerings. Concurrently, Alcon Inc. has strengthened its international presence by opening its second training center in partnership with the Aravind Eye Care System in India on July 24, expanding access to phacoemulsification training and advanced eye care technology. The contrast between Alcon's diversified global infrastructure and RxSight's focused, high-growth technology platform illustrates two distinct operational profiles within the eye care sector. Could Alcon Inc. (ALC) and RxSight, Inc. (RXST)’s Partnership Reshape the Future of Cataract Surgery? Q1 2026 Financial Snapshot: High-Margin Scale vs. Growth Transition Looking at both companies' latest First Quarter 2026 financial reports highlights the contrast between a global blue-chip conglomerate and a commercial-stage medtech growth play. Alcon Inc. (NYSE:ALC) delivered a strong Q1 2026, generating $2.7 billion in net sales, up 10% year-over-year (6% in constant currency), which was driven by surgical sales of $1.5 billion (+10%) and Vision Care sales of $1.2 billion (+9%). Growth was fueled by new product rollouts, including the Unity VCS and CS surgical platforms, PanOptix Pro, and Tryptyr dry-eye treatments. The firm's core diluted earnings per share jumped 16% to $0.85, while core operating margin expanded to 21.2%. Although IFRS reported that its EPS dropped to $0.39 due to one-off costs and $33 million in tariff headwinds, Alcon's underlying cash generation remained rock solid with $279 million in free cash flow, allowing the board to authorize a new $1.5 billion share repurchase program. On the other hand, RxSight, Inc. (NASDAQ:RXST)'s Q1 2026 performance reflected a company navigating capital spending slowdowns. Revenue fell 18.5% year-over-year to $30.9 million, hit by lower sales of its Light Delivery Devices (LDDs). LAL procedure volume held roughly flat, down 0.4% to 27,472 units, while 20 new LDDs were placed, expanding its installed base to 1,154 units. However, RXST's gross profit margin expanded to 76.1% (up from 74.8%) due to a higher ratio of high-margin lens sales relative to hardware sales. Increased commercial hiring pushed operating expenses to $41.3 million, widening its net loss to $15.9 million ($0.38 per share). Management reiterated full-year revenue guidance of $120 million to $135 million, backed by a strong cash reserve of $217.9 million. Story Continues Alcon Inc. (NYSE:ALC) vs RxSight, Inc. (NASDAQ:RXST): Which Company Is Performing Better? On absolute financial health, cash generation, and market scale, Alcon is the stronger, lower-risk compounder. It operates as...
🔥 EXCLUSIVE PARTNER OFFER
Dewalt brushless impact drill, DCF887 205N. M, 20V Dewalt battery wireless screwdriver
Special Price
🎁 Special promotion! Perfect gift idea at an unbeatable price. Shop now!
Affiliate link — Commission earned at no extra cost to you
© EcoNews DZ — Global Economic & Financial News
Comments
Post a Comment